Patents by Inventor Jon E. Chatterton

Jon E. Chatterton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Interfering RNA delivery system and uses thereof
    Patent number: 8664375
    Abstract: The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: March 4, 2014
    Assignee: Alcon Research, Ltd.
    Inventor: Jon E. Chatterton
  • SIRNA TARGETING VEGFA AND METHODS FOR TREATMENT IN VIVO
    Publication number: 20140031414
    Abstract: Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.
    Type: Application
    Filed: August 27, 2013
    Publication date: January 30, 2014
    Applicants: ALCON RESEARCH, LTD., THERMO FISHER SCIENTIFIC BIOSCIENCES INC.
    Inventors: Anja Smith, Angela Reynolds, Jon E. Chatterton, Xinyu Zhang
  • LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
    Publication number: 20140018296
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.
    Type: Application
    Filed: September 23, 2013
    Publication date: January 16, 2014
    Applicant: Alcon Research, Ltd.
    Inventor: Jon E. Chatterton
  • RNAi-mediated inhibition of histamine receptor H1-related conditions
    Patent number: 8618278
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: December 31, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
    Publication number: 20130338213
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Application
    Filed: August 22, 2013
    Publication date: December 19, 2013
    Applicant: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller
  • Low density lipoprotein receptor-mediated siRNA delivery
    Patent number: 8569258
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: October 29, 2013
    Assignee: Alcon Research, Ltd.
    Inventor: Jon E. Chatterton
  • siRNA targeting VEGFA and methods for treatment in vivo
    Patent number: 8546349
    Abstract: Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: October 1, 2013
    Assignees: Thermo Fisher Scientific Biosciences Inc., Alcon Research, Ltd.
    Inventors: Anja Smith, Angela Reynolds, Jon E. Chatterton, Xinyu Zhang
  • RNAi-mediated inhibition of tumor necrosis factor ?-related conditions
    Patent number: 8541389
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: September 24, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller
  • RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20130245098
    Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: May 29, 2013
    Publication date: September 19, 2013
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Jon E. Chatterton, David P. Bingaman
  • RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
    Patent number: 8471000
    Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: June 25, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: Jon E. Chatterton, David P. Bingaman
  • Transferrin/transferrin receptor-mediated siRNA delivery
    Patent number: 8399653
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: March 19, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: Jon E. Chatterton, Abbot F. Clark
  • LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
    Publication number: 20120315288
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.
    Type: Application
    Filed: August 13, 2012
    Publication date: December 13, 2012
    Applicant: ALCON RESEARCH, LTD.
    Inventor: Jon E. Chatterton
  • RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions
    Publication number: 20120264809
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Application
    Filed: June 11, 2012
    Publication date: October 18, 2012
    Applicant: ALCON RESEARCH, LTD.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20120245217
    Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: May 17, 2012
    Publication date: September 27, 2012
    Applicant: Alcon Research, Ltd.
    Inventors: Jon E. Chatterton, David P. Bingaman
  • Low density lipoprotein receptor-mediated siRNA delivery
    Patent number: 8268798
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: September 18, 2012
    Assignee: Alcon Research, Ltd.
    Inventor: Jon E. Chatterton
  • RNAi-mediated inhibition of histamine receptor H1-related conditions
    Patent number: 8222227
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: July 17, 2012
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-Mediated Inhibition of RHO Kinase for Treatment of Ocular Disorders
    Publication number: 20120178794
    Abstract: RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.
    Type: Application
    Filed: March 26, 2012
    Publication date: July 12, 2012
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Jon E. Chatterton, Abbot F. Clark
  • RNAI-MEDIATED INHIBITION OF FRIZZLED RELATED PROTEIN-1 FOR TREATMENT OF GLAUCOMA
    Publication number: 20120178795
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Application
    Filed: March 26, 2012
    Publication date: July 12, 2012
    Applicant: NOVARTIS AG
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E. Chatterton
  • Excitatory glycine receptors and methods
    Patent number: 8193315
    Abstract: The invention provides isolated N-methyl-D-aspartate type 3B (NR3B) polypeptides, functional fragments and peptides, encoding nucleic acid molecules and polynucleotides, and specific antibodies. Also provided are excitatory glycine receptors, containing either NR3B or NR3A polypeptides. Further provided are methods for detecting excitatory glycine receptor ligands, agonists and antagonists. The invention also provides related diagnostic and therapeutic methods.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: June 5, 2012
    Assignees: Sanford-Burnham Medical Research Institute, Yale University, The Brigham and Women's Hospital, Inc.
    Inventors: Stuart A. Lipton, Dongxian Zhang, Jon E. Chatterton, Kevin A. Sevarino, Marc Awobuluyi
  • RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
    Patent number: 8173617
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: May 8, 2012
    Assignee: Novartis AG
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E. Chatterton